NMD Pharma is about to start a combined Phase I/IIa clinical trial with its ClC-1 channel inhibitor in healthy subjects and patients with myasthenia gravis

NMD Pharma, a drug discovery company that develops novel treatments of neuromuscular disorders, announced that it has received approval from the Dutch ethics committee and regulatory authorities to advance its small molecule inhibitor of skeletal muscle specific ClC-1 ion channel (NMD670) into clinical trials as a novel treatment for the symptoms of myasthenia gravis.

Myasthenia gravis is an autoimmune neuromuscular disease that causes skeletal muscle weakness due to the defective communication between nerves and muscles. In preclinical studies, ClC-1 inhibition has been shown to improve neuromuscular transmission and ameliorate skeletal muscle function.

The new Phase I/IIa clinical trial is designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of NMD670.

Read the press release here.

Read more about NMD Pharma here.

Photo by Marcelo Leal on Unsplash